SCHEMBL3572145

SCHEMBL3572145

CCOC(=O)c1csc(C2CCN(C(=O)OC(C)(C)C)C2c2cc(C)nc(-n3ccnc3)n2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
NR1H3 Q13133 1/20 0.43
NOS2 P35228 5/20 0.38
NOS1 P29475 4/20 0.38
GAA P10253 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33
CASP8 Q14790 1/20 0.33
UCHL1 P09936 1/20 0.33
USP30 Q70CQ3 1/20 0.33
LMNA P02545 1/20 0.33
ABCB1 P08183 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568596 0.84 NOS2 (0.39) NOS2NOS1GPR119
SCHEMBL3563497 0.82 NOS2 (0.41) NOS2NOS1KDM4ETSHRMAPK1
SCHEMBL3558612 0.81 NOS2 (0.37) NOS2NOS1GAAKDM4ETSHR
SCHEMBL5201529 0.81 NR1H2 (0.43) NR1H2NR1H3GAAATMSMN1; SMN2
SCHEMBL3562104 0.79 NOS2 (0.50) NOS2NOS1
SCHEMBL13037198 0.79 NOS2 (0.46) NOS2NOS1
SCHEMBL3564331 0.77 NOS2 (0.41) NOS2NOS1KDM4ETSHRMAPK1
SCHEMBL3564512 0.76 NOS2 (0.40) NOS2NOS1KDM4ETSHRMAPK1
SCHEMBL3566417 0.76 NOS2 (0.42) NOS2NOS1GPR119
SCHEMBL3564772 0.76 NOS2 (0.53) NOS2NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
US-7825256-B2 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. (US) 2010-11-02 US disclosed
EP-1817030-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS Kalypsys, Inc. (US) 2007-08-15 EP disclosed
WO-2006060424-A2 INDUCIBLE NITRIC OXIDE SYNTHASE DIMERIZATION INHIBITORS KALYPSYS, INC. (US) 2006-06-08 WO disclosed
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors KALYPSYS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116515-A1 Inducible nitric oxide synthase dimerization inhibitors NOS3, NOS2, NOS1 NR1H2 156/4885NR1H3 150/4885NOS2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.